Integrating imaging and RNA-seq improves outcome prediction in cervical cancer.
Cancer
Genetics
Oncology
Radiation therapy
Transcription
Journal
The Journal of clinical investigation
ISSN: 1558-8238
Titre abrégé: J Clin Invest
Pays: United States
ID NLM: 7802877
Informations de publication
Date de publication:
01 03 2021
01 03 2021
Historique:
received:
20
04
2020
accepted:
22
12
2020
entrez:
1
3
2021
pubmed:
2
3
2021
medline:
21
9
2021
Statut:
ppublish
Résumé
Approaches using a single type of data have been applied to classify human tumors. Here we integrate imaging features and transcriptomic data using a prospectively collected tumor bank. We demonstrate that increased maximum standardized uptake value on pretreatment 18F-fluorodeoxyglucose-positron emission tomography correlates with epithelial-to-mesenchymal transition (EMT) gene expression. We derived and validated 3 major molecular groups, namely squamous epithelial, squamous mesenchymal, and adenocarcinoma, using prospectively collected institutional (n = 67) and publicly available (n = 304) data sets. Patients with tumors of the squamous mesenchymal subtype showed inferior survival outcomes compared with the other 2 molecular groups. High mesenchymal gene expression in cervical cancer cells positively correlated with the capacity to form spheroids and with resistance to radiation. CaSki organoids were radiation-resistant but sensitive to the glycolysis inhibitor, 2-DG. These experiments provide a strategy for response prediction by integrating large data sets, and highlight the potential for metabolic therapy to influence EMT phenotypes in cervical cancer.
Identifiants
pubmed: 33645544
pii: 139232
doi: 10.1172/JCI139232
pmc: PMC7919714
doi:
pii:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCI NIH HHS
ID : K08 CA237822
Pays : United States
Organisme : NCI NIH HHS
ID : K22 CA237839
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA181745
Pays : United States
Références
Cancer. 2010 Mar 15;116(6):1469-75
pubmed: 20108309
Cancer Metab. 2016 Oct 17;4:19
pubmed: 27777765
Cancer Lett. 2015 Aug 1;364(1):44-58
pubmed: 25917568
Int J Cancer. 2020 Apr 1;146(7):2047-2058
pubmed: 31732968
Clin Cancer Res. 2012 Mar 1;18(5):1464-71
pubmed: 22235101
Nature. 2017 Mar 16;543(7645):378-384
pubmed: 28112728
J Biol Chem. 2016 Jun 17;291(25):12917-29
pubmed: 27129262
Br J Cancer. 2017 Jan;116(3):362-369
pubmed: 28072763
Virology. 2009 Aug 15;391(1):57-63
pubmed: 19552933
Int J Radiat Oncol Biol Phys. 2011 Jun 1;80(2):429-36
pubmed: 20542643
Cancer Inform. 2009 Aug 05;7:199-216
pubmed: 19718451
Lancet Glob Health. 2020 Feb;8(2):e191-e203
pubmed: 31812369
Cancer Res. 2018 Mar 15;78(6):1392-1403
pubmed: 29339540
FASEB J. 2016 Sep;30(9):3001-10
pubmed: 27279361
Cancer. 2007 Oct 15;110(8):1738-44
pubmed: 17786947
Cancer Res. 2010 Feb 15;70(4):1441-8
pubmed: 20124485
Clin Chem. 2014 Jan;60(1):144-6
pubmed: 24046199
Clin Cancer Res. 2013 Jan 1;19(1):279-90
pubmed: 23091115
Prev Med. 2020 Feb;131:105968
pubmed: 31881235